Entera Bio Ltd. (ENTX) stock
ENTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.11−0.11 (-3.42%)
Close on Nov 13, 2026Market cap $538.47MP/E –Yield –
Entera Bio profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Entera Bio's profit margin for the twelve months ending Dec 31, 2025 was -27235.7%. For fiscal 2025 it was -27235.7%, against -5271.3% the year before. The highest annual figure on record is -2134.3% in fiscal 2021.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -27235.7% | −21964.4 |
| FY2024 | Dec 31, 2024 | -5271.3% | +4483.2 |
| FY2022 | Dec 31, 2022 | -9754.5% | −7620.2 |
| FY2021 | Dec 31, 2021 | -2134.3% | +938.6 |
| FY2020 | Dec 31, 2020 | -3072.9% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2025 | Mar 31, 2025 | -6111.9% | +15566.7 |
| Q4 FY2024 | Dec 31, 2024 | -2875.6% | +35461.9 |
| Q3 FY2024 | Sep 30, 2024 | -7192.9% | +45.8 |
| Q2 FY2024 | Jun 30, 2024 | -3763.2% | +1801.5 |
| Q4 FY2022 | Dec 31, 2022 | -21678.6% | −19193.7 |
| Q3 FY2022 | Sep 30, 2022 | -38337.5% | −36041.8 |
| Q2 FY2022 | Jun 30, 2022 | -7238.6% | −4874.4 |
| Q1 FY2022 | Mar 31, 2022 | -5564.7% | −4102.3 |
| Q4 FY2021 | Dec 31, 2021 | -2484.8% | – |
| Q3 FY2021 | Sep 30, 2021 | -2295.7% | – |
| Q2 FY2021 | Jun 30, 2021 | -2364.2% | – |
| Q1 FY2021 | Mar 31, 2021 | -1462.4% | – |
See a number that looks wrong?